This data indicates that CRKL is a potential therapeutic target for ALK-rearranged NSCLC, and provides a proof-of-concept for the combination of ALK and CRKL inhibitors as a therapeutic strategy. This evidence concerns the gene CRKL and non-small cell lung carcinoma.